EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension

Maki Niihori iD, Joel James iD, Mathews V Varghese iD, Nolan McClain iD, Odunayo Susan Lawal iD, Rohit C Philip iD, Brenda K Baggett iD, Dmitry A Goncharov iD, Vinicio de Jesus Perez iD, Elena A Goncharova iD, Ruslan Rafikov iD, Olga Rafikova iD

Journal of Experimental Medicine · 04.11.2024 · 221 (11)

DOI: 10.1084/jem.20231568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 25.09.2024. Verfasst von Maki Niihori und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Mitochondria, Thioctic Acid. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: American Heart Association, Cardiovascular Medical Research and Education Fund, American Heart Association-American Stroke Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Impaired pulmonary angiogenesis plays a pivotal role in the progression of pulmonary arterial hypertension (PAH) and patient mortality, yet the molecular mechanisms driving this process remain enigmatic. Our study uncovered a striking connection between mitochondrial dysfunction (MD), caused by a humanized mutation in the NFU1 gene, and severely disrupted pulmonary angiogenesis in adult lungs. Restoring the bioavailability of the NFU1 downstream target, lipoic acid (LA), alleviated MD and angiogenic deficiency and rescued the progressive PAH phenotype in the NFU1G206C model. Notably, significant NFU1 expression and signaling insufficiencies were also identified in idiopathic PAH (iPAH) patients’ lungs, emphasizing this study’s relevance beyond NFU1 mutation cases. The remarkable improvement in mitochondrial function of PAH patient-derived pulmonary artery endothelial cells (PAECs) following LA supplementation introduces LA as a potential therapeutic approach. In conclusion, this study unveils a novel role for MD in dysregulated pulmonary angiogenesis and PAH manifestation, emphasizing the need to correct MD in PAH patients with unrecognized NFU1/LA deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaThioctic AcidHumansAnimalsEndothelial CellsPulmonary Arterial HypertensionNeovascularization, PathologicMiceMalePulmonary ArteryLungMutationFemaleFamilial Primary Pulmonary HypertensionMice, Inbred C57BLSignal TransductionHypertension, Pulmonary

Substanzen

Thioctic Acid

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN, USA.
  • Department of Medicine, University of Arizona, Tucson, AZ, USA.
  • Department of Electrical and Computer Engineering, University of Arizona College of Engineering, Tucson, AZ, USA.
  • Department of Medical Imaging, University of Arizona College of Medicine, Tucson, AZ, USA.
  • The University of Arizona Cancer Center, University of Arizona , Tucson, AZ, USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Lung Center, University of California, Davis School of Medicine, Davis, CA, USA.

ORCID-Profile: Maki Niihori, Joel James, Mathews V Varghese, Nolan McClain, Odunayo Susan Lawal, Rohit C Philip, Brenda K Baggett, Dmitry A Goncharov, Vinicio de Jesus Perez, Elena A Goncharova, Ruslan Rafikov, Olga Rafikova

Förderung

  • American Heart Association
  • Cardiovascular Medical Research and Education Fund
  • American Heart Association-American Stroke Association
  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Niihori, M., James, J., Varghese, M. V., McClain, N., Lawal, O. S., Philip, R. C., Baggett, B. K., Goncharov, D. A., de Jesus Perez, V., Goncharova, E. A., Rafikov, R., & Rafikova, O. (2024). Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension. Journal of Experimental Medicine, 221(11). https://doi.org/10.1084/jem.20231568

Vancouver

Niihori M, James J, Varghese MV, McClain N, Lawal OS, Philip RC, et al. Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension. Journal of Experimental Medicine. 2024;221(11). doi:10.1084/jem.20231568

BibTeX
@article{Niihori2024,
  author = {Niihori, Maki and James, Joel and Varghese, Mathews V and McClain, Nolan and Lawal, Odunayo Susan and Philip, Rohit C and Baggett, Brenda K and Goncharov, Dmitry A and de Jesus Perez, Vinicio and Goncharova, Elena A and Rafikov, Ruslan and Rafikova, Olga},
  title = {Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {11},
  doi = {10.1084/jem.20231568}
}
Kostenlos starten →